Clinical Trial Protocol Description:
This Phase 3 clinical trial is evaluating a potential new treatment for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy.
The study will compare an investigational treatment with a standard treatment to determine whether it can help participants live longer and slow the progression of their cancer. Researchers will also evaluate safety, quality of life, pain, and other measures of treatment effectiveness.
Approximately 1,440 participants will be enrolled worldwide. Eligible participants will be randomly assigned to receive one of two study treatments administered by IV infusion every three weeks. Study-related assessments may include physical exams, blood tests, imaging scans, and questionnaires.
Participants may remain in the study for up to two years and will be monitored throughout the study for treatment response and safety. An independent committee will regularly review study data to help ensure participant safety.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Are male and 18 years of age or older.
- Have advanced prostate cancer that has spread to other parts of the body and is no longer responding to hormone therapy (mCRPC).
- Have experienced disease progression while receiving hormone therapy.
- Have previously received one or two hormone-targeting treatments for advanced prostate cancer.
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.
Study Details
Clinical Trial Investigator
Contact Information